carmustine has been researched along with Minimal Disease, Residual in 10 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "46 patients with Hodgkin's disease received Dexa-BEAM chemotherapy followed by radiotherapy." | 1.31 | [The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)]. ( Dzhumabaeva, BT; Efimov, IV; Kaplanskaia, IB; Margolin, OV; Moiseeva, TN; Pivnik, AV; Rasstrigin, NA; Roshchina, LS; Shavlokhov, VS; Sotnikov, VM; Stroiakovskiĭ, DL, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sobol, U | 1 |
| Rodriguez, T | 1 |
| Smith, S | 1 |
| Go, A | 1 |
| Vimr, R | 1 |
| Parthasarathy, M | 1 |
| Guo, R | 1 |
| Stiff, P | 1 |
| Kolstad, A | 1 |
| Laurell, A | 1 |
| Jerkeman, M | 1 |
| Grønbæk, K | 1 |
| Elonen, E | 1 |
| Räty, R | 1 |
| Pedersen, LB | 1 |
| Loft, A | 1 |
| Bogsrud, TV | 1 |
| Kimby, E | 1 |
| Hansen, PB | 1 |
| Fagerli, UM | 1 |
| Nilsson-Ehle, H | 1 |
| Lauritzsen, GF | 1 |
| Lehmann, AK | 1 |
| Sundstrom, C | 1 |
| Karjalainen-Lindsberg, ML | 1 |
| Ralfkiaer, E | 1 |
| Ehinger, M | 1 |
| Delabie, J | 1 |
| Bentzen, H | 1 |
| Schildt, J | 1 |
| Kostova-Aherdan, K | 1 |
| Frederiksen, H | 1 |
| Brown, Pde N | 1 |
| Geisler, CH | 1 |
| Paiva, B | 1 |
| Vidriales, MB | 1 |
| Cerveró, J | 1 |
| Mateo, G | 1 |
| Pérez, JJ | 1 |
| Montalbán, MA | 1 |
| Sureda, A | 1 |
| Montejano, L | 1 |
| Gutiérrez, NC | 1 |
| García de Coca, A | 1 |
| de Las Heras, N | 1 |
| Mateos, MV | 1 |
| López-Berges, MC | 1 |
| García-Boyero, R | 1 |
| Galende, J | 1 |
| Hernández, J | 1 |
| Palomera, L | 1 |
| Carrera, D | 1 |
| Martínez, R | 1 |
| de la Rubia, J | 1 |
| Martín, A | 1 |
| Bladé, J | 1 |
| Lahuerta, JJ | 1 |
| Orfao, A | 1 |
| San Miguel, JF | 1 |
| Barlogie, B | 1 |
| Epstein, J | 1 |
| Shaughnessy, JD | 1 |
| Hsiao, PF | 1 |
| Hsiao, CH | 1 |
| Tsai, TF | 1 |
| Jee, SH | 1 |
| Dreger, P | 1 |
| Brand, R | 1 |
| Michallet, M | 1 |
| Kobiakov, GL | 1 |
| Stroiakovskiĭ, DL | 1 |
| Pivnik, AV | 1 |
| Shavlokhov, VS | 1 |
| Sotnikov, VM | 1 |
| Moiseeva, TN | 1 |
| Rasstrigin, NA | 1 |
| Margolin, OV | 1 |
| Efimov, IV | 1 |
| Dzhumabaeva, BT | 1 |
| Kaplanskaia, IB | 1 |
| Roshchina, LS | 1 |
| Meloni, G | 1 |
| Proia, A | 1 |
| Guerrisi, V | 1 |
| Cordone, I | 1 |
| De Cuia, R | 1 |
| Fenu, S | 1 |
| Mauro, FR | 1 |
| Pescarmona, E | 1 |
| Reato, G | 1 |
| Mandelli, F | 1 |
| Vose, JM | 1 |
| Sharp, G | 1 |
| Chan, WC | 1 |
| Nichols, C | 1 |
| Loh, K | 1 |
| Inwards, D | 1 |
| Rifkin, R | 1 |
| Bierman, PJ | 1 |
| Lynch, JC | 1 |
| Weisenburger, DD | 1 |
| Kessinger, A | 1 |
| Armitage, JO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| High-dose Therapy With Autologous Stem Cell Support in First Line Treatment of Mantle Cell Lymphoma- 90Y-Ibritumomab Tiuxetan in Combination With BEAM or BEAC to Improve Outcome for Patients Not in CR After Induction Treatment[NCT00514475] | Phase 2 | 160 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study[NCT03421132] | 250 participants (Anticipated) | Observational | 2018-02-20 | Recruiting | |||
| Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Resp[NCT00560053] | Phase 3 | 500 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment[NCT06109233] | 80 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carmustine and Minimal Disease, Residual
| Article | Year |
|---|---|
Autologous stem cell transplantation for chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Ca | 2007 |
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
3 trials available for carmustine and Minimal Disease, Residual
| Article | Year |
|---|---|
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Com | 2014 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 2002 |
5 other studies available for carmustine and Minimal Disease, Residual
| Article | Year |
|---|---|
Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease Progression; Etoposi | 2014 |
Going with the flow, and beyond, in myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Dexam | 2008 |
Minimal residual disease in hypopigmented mycosis fungoides.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Carmustine; Humans; Male; Mycosis Fungoides; Neoplasm | 2006 |
[The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvan | 2000 |
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carm | 2000 |